<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molecular tests in diffuse gliomas in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molecular tests in diffuse gliomas in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Molecular tests in diffuse gliomas in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Test</td> <td class="subtitle1">Method(s) of testing</td> <td class="subtitle1">Clinical implications and notes</td> </tr> <tr> <td><em>IDH1/2</em> mutation</td> <td>IHC for R132H-mutant IDH1*, sequencing of <em>IDH1/2</em></td> <td>IDH1 IHC is required for all diffuse gliomas; when negative, sequencing of <em>IDH1/2</em> should be prioritized for grade 2 and 3 gliomas and for glioblastoma in patients &lt;55 years old; IDH mutations confer improved prognosis across all tumor grades.</td> </tr> <tr> <td><em>MGMT</em> promotor methylation</td> <td>Methylation-specific PCR, array-based methylation assay</td> <td>Methylation confers improved prognosis in high-grade gliomas and is predictive of improved responsiveness to alkylating-agent chemotherapy; no diagnostic value.</td> </tr> <tr> <td>1p/19q codeletion</td> <td>FISH, LOH assay, aCGH, MLPA, PCR-based</td> <td>Required for diffuse gliomas with oligodendroglial component; not routinely performed on glioblastoma specimens; indicated when oligodendroglial pattern predominates to help distinguish between glioblastoma and grade 3 oligodendroglioma; in the absence of an IDH mutation, codeletion by FISH should raise suspicion for partial or incomplete deletions, which are associated with some IDH-wildtype astrocytomas and a worse prognosis.</td> </tr> <tr> <td><em>ATRX</em> mutations</td> <td>IHC for nuclear ATRX expression or sequencing</td> <td>Loss of nuclear staining indicates the presence of an <em>ATRX</em> mutation, strongly associated with astrocytic lineage; <em>ATRX</em> mutations are mutually exclusive with 1p/19q codeletion but should not be used as a substitute for 1p/19q testing.</td> </tr> <tr> <td><em>TERT</em> promotor mutations</td> <td>Sequencing</td> <td><em>TERT</em> mutations occur in IDH-wildtype diffuse astrocytomas and in IDH-mutant 1p/19q-codeleted oligodendrogliomas; in IDH-wildtype astrocytomas, <em>TERT</em> mutations are associated with poor prognosis and establish a diagnosis of glioblastoma independent of histologic features.</td> </tr> <tr> <td><em>TP53</em></td> <td>IHC for mutant p53</td> <td>Mutant p53 staining is present in vast majority of astrocytic tumors but is not entirely sensitive or specific for astrocytic differentiation; no independent clinical or prognostic implications beyond assisting in pathologic diagnosis.</td> </tr> <tr> <td><em>EGFR</em> amplification and mutations</td> <td>FISH, aCGH, sequencing</td> <td><em>EGFR</em> amplification is specific but not sensitive for glioblastoma; results may be relevant for clinical trials but no current therapeutic implications. In IDH-wildtype astrocytomas, <em>EGFR</em> amplification establishes a diagnosis of glioblastoma independent of histologic features.</td> </tr> <tr> <td>Gain of chromosome 7/loss of 10q</td> <td>FISH, aCGH</td> <td>Combination of tri/polysomy 7 and LOH 10q in an IDH-wildtype diffuse astrocytoma is associated with aggressive clinical course and establishes a diagnosis of glioblastoma independent of histologic features; often seen along with <em>TERT</em> mutations and <em>EGFR</em> amplification.</td> </tr> <tr> <td><em>PTEN</em> mutations</td> <td>Sequencing</td> <td>Occurs in 20 to 30% of glioblastomas, as a rule accompanied by LOH 10q; may be relevant for clinical trials but has low diagnostic value and no current therapeutic implications.</td> </tr> <tr> <td><em>BRAF</em> V600E mutations</td> <td>IHC for V600E-mutant BRAF or <em>BRAF</em> sequencing</td> <td>Rare in glioblastoma and adult low-grade glioma (&lt;5%) but has clinical trial and potential therapeutic implications.</td> </tr> <tr> <td>Histone <em>H3F3A</em> and <em>HIST1H3B</em> mutations</td> <td>IHC for K27M and G34 mutations, sequencing</td> <td>K27M mutations mostly found in pediatric and young adult midline gliomas; young adult high-grade gliomas of the cortex may have <em>H3F3A</em> G34R/V mutations, usually combined with <em>ATRX</em> and <em>TP53</em> mutations; usually associated with poor prognosis.</td> </tr> <tr> <td><em>CDKN2A/B</em> deletion</td> <td>FISH, aCGH, sequencing</td> <td>Negative prognostic marker when present in IDH-mutant diffuse gliomas; in IDH-mutant astrocytoma, <em>CDKN2A/B</em> deletion establishes the tumor as grade 4, even in the absence of high-grade histology.</td> </tr> <tr> <td><em>NTRK</em> fusions</td> <td>FISH, sequencing fusion assays</td> <td>Rare in adult gliomas but potentially treatable with TRK inhibitors.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p><em>IDH1/2</em>: isocitrate dehydrogenase type 1 or type 2; 
		IHC: immunohistochemistry; 
		<em>MGMT</em>: O6-methylguanine-DNA methyltransferase; 
		PCR: polymerase chain reaction; 
		FISH: fluorescence in situ hybridization; 
		LOH: loss of heterozygosity; 
		aCGH: array comparative genomic hybridization; 
		MLPA: multiplex ligation-dependent probe amplification; 
		<em>ATRX</em>: alpha-thalassemia/mental retardation syndrome X-linked; 
		<em>TERT</em>: telomerase reverse transcriptase; 
		<em>EGFR</em>: epidermal growth factor receptor; 
		<em>PTEN</em>: phosphatase and tensin homolog; 
		<em>CDKN2A/B</em>: cyclin-dependent kinase inhibitor 2A/B; 
		<em>NTRK</em>: neurotrophic receptor tyrosine kinase.</p>
	
	* Most common IDH mutation in diffuse gliomas (approximately 90%).</div><div class="graphic_reference">References:
	<ol>
<li>van den Bent MJ, Weller M, Wen PY, et al. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 2017; 19:614.</li>
<li>WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6).</li>
</ol></div><div id="graphicVersion">Graphic 115919 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
